1. Home
  2. ENTX vs SQNS Comparison

ENTX vs SQNS Comparison

Compare ENTX & SQNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.61

Market Cap

142.0M

Sector

Health Care

ML Signal

HOLD

Logo Sequans Communications S.A.

SQNS

Sequans Communications S.A.

HOLD

Current Price

$4.98

Market Cap

85.3M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTX
SQNS
Founded
2010
2003
Country
Israel
France
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
142.0M
85.3M
IPO Year
2018
2011

Fundamental Metrics

Financial Performance
Metric
ENTX
SQNS
Price
$1.61
$4.98
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$10.00
$21.33
AVG Volume (30 Days)
140.2K
152.9K
Earning Date
11-14-2025
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$124,000.00
$31,534,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$70.61
P/E Ratio
N/A
N/A
Revenue Growth
25.25
3.20
52 Week Low
$1.50
$4.44
52 Week High
$3.22
$58.30

Technical Indicators

Market Signals
Indicator
ENTX
SQNS
Relative Strength Index (RSI) 32.84 42.74
Support Level $1.53 $4.44
Resistance Level $1.99 $4.88
Average True Range (ATR) 0.18 0.29
MACD -0.00 0.02
Stochastic Oscillator 13.56 42.07

Price Performance

Historical Comparison
ENTX
SQNS

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About SQNS Sequans Communications S.A.

Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.

Share on Social Networks: